Skip to main content
Log in

The SOHO (Schizophrenia Outpatient Health Outcome) Study

Implications for the Treatment of Schizophrenia

  • Commentary
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

The European SOHO (Schizophrenia Outpatient Health Outcome) study is an observational, naturalistic study of the outpatient treatment of schizophrenia. The patient recruitment and assessment began in September 2000 and finished in early 2005. A total of 10 972 adult patients from ten European countries who were initiating or changing antipsychotic medication for the treatment of schizophrenia within the normal course of care have been enrolled. The patients have been followed at regular intervals over the 3-year timeframe of the study. Evaluation includes clinical severity, measured with the Clinical Global Impression (CGI) scale; health-related quality of life; social functioning; and medication tolerability.

The 6- and 12-month results have been published so far and have demonstrated that the patients in whom treatment was initiated with olanzapine or clozapine or who were started on more than one antipsychotic of any class at baseline tended to have somewhat greater improvement than patients treated with other atypical or typical antipsychotics, both in terms of symptoms measured with the CGI and quality of life. Numbers of social contacts increased with the treatment, but other aspects of social functioning did not show any significant change.

Atypical antipsychotics as a class were associated with a lower frequency of extrapyramidal symptoms (EPS) and anticholinergic use than typical antipsychotics. The frequency of EPS was lowest in the clozapine-, quetiapine- and olanzapine-treated patients, at around 10%. The atypical antipsychotics also conferred a lower risk for tardive dyskinesia than the typical antipsychotics. Weight gain occurred in all treatment cohorts over the first 12 months of treatment and was statistically significantly greater in the patients who started treatment with olanzapine and clozapine. Prolactin- and sexually-related adverse events were frequent at baseline assessment: amenorrhoea was present in around one- third of women, impotence in around 40% of men, and loss of libido in 50% of both male and female patients. Patients treated with olanzapine, clozapine and quetiapine were significantly less likely to have sexual/endocrine-related dysfunctions after 6 months of treatment (the 12-month results of this parameter are yet to be published) than those in the other treatment cohorts (typical antipsychotics, risperidone and amisulpride). Concomitant medication use during the study has been high, ranging from 5% to 29% for anticholinergics, 8% to 23% for antidepressants, 22% to 37% for anxiolytics and 7% to 19% for mood stabilisers, depending on the type of antipsychotic prescribed. Fewer olanzapine-, quetiapine- and clozapine-treated patients used concomitant anticholinergics or anxiolytics/hypnotics.

The current results from the SOHO study indicate that differences in effectiveness and tolerability do exist between the antipsychotics. Future results from the study will be published during the coming months and years, and will allow patterns of antipsychotic use in routine clinical practice (including how often and why changes are made) to be determined. This important information is likely to impact on the future use of antipsychotics and will assist clinicians in refining the use of these drugs and improving the outcome of patients to whom they are prescribed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19: 287–302

    Article  PubMed  CAS  Google Scholar 

  2. Keith SJ. Pharmacologic advances in the treatment of schizophrenia. N Engl J Med 1997; 337: 851–2

    Article  PubMed  CAS  Google Scholar 

  3. Kane JM. Drug therapy: schizophrenia. N Engl J Med 1996; 334: 34–41

    Article  PubMed  CAS  Google Scholar 

  4. Marder SR. Antipsychotic drugs and relapse prevention. Schizophr Res 1999; 35: 87–92

    Article  Google Scholar 

  5. Cassens G, Inglis AK, Appelbaum PS, et al. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990; 16: 477–49

    Article  PubMed  CAS  Google Scholar 

  6. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989; 98: 367–80

    Article  PubMed  CAS  Google Scholar 

  7. Marder SR, Asarnow RF, Van Putten T. Information processing and neuroleptic response in acute and stabilised schizophrenic patients. Psychiatry Research 1984; 13: 41–9

    Article  PubMed  CAS  Google Scholar 

  8. Strauss ME, Reynolds KS, Jayaram G, et al. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res 1990; 3: 127–9

    Article  PubMed  CAS  Google Scholar 

  9. Weiden PJ, Shaw E, Man JJ. Causes of neuroleptic noncompliance. Psychiatr Ann 1986; 16: 571–5

    Google Scholar 

  10. Fleischhacker WW. The psychopharmacology of schizophrenia. Curr Opin Psychiatry 1999; 12: 53–9

    Article  Google Scholar 

  11. Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58: 205–11

    Article  PubMed  CAS  Google Scholar 

  12. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457–65

    PubMed  CAS  Google Scholar 

  13. Lindenmayer JP, Iskander A, Park M, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 1998; 59: 521–7

    Article  PubMed  CAS  Google Scholar 

  14. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 2001; 48: 17–28

    Article  PubMed  CAS  Google Scholar 

  15. Green MF, Marshall BD, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154: 799–804

    PubMed  CAS  Google Scholar 

  16. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000; 57: 249–58

    Article  PubMed  CAS  Google Scholar 

  17. Kopelowicz A, Zarate R, Tripodis K, et al. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000; 157: 987–93

    Article  PubMed  CAS  Google Scholar 

  18. McEvoyu JP, Scheifler PL, Frances A. Expert consensus guidelines series: treatment of schizophrenia 1999. J Clin Psychiatry 1999; 60Suppl. 11: 12–3

    Google Scholar 

  19. Spanish Psychiatric Association (Sociedad Española de Psiquiatria). Expert Spanish consensus for recommendations in the treatment of schizophrenia. Madrid: Sociedad Española de Psiquiatria, 2000

    Google Scholar 

  20. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161(2 Suppl.): 1–56

    PubMed  Google Scholar 

  21. Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999; 60: 649–57

    Article  PubMed  CAS  Google Scholar 

  22. Hofer A, Hummer M, Huber R, et al. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 2000; 20: 699–702

    Article  PubMed  CAS  Google Scholar 

  23. Haro JM, Edgell ET, Frewer P, et al., on behalf of the SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand 2003; 107Suppl. 416: 1–9

    Google Scholar 

  24. Guy W. Clinical global impression. In: ECDEU assessment manual for psychopharmacology, revised. Rockville (MD): National Institute of Mental Health, 1976

    Google Scholar 

  25. Haro JM, Kamath SA, Ochoa S, et al., on behalf of the SOHO Study Group. The Clinical Global Impression-Schizophrenia (CGI-SCH) scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003; 107Suppl. 416: 16–23

    Article  Google Scholar 

  26. Haro JM, Edgell ET, Novick D, et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005; 111: 220–31

    Article  PubMed  CAS  Google Scholar 

  27. Lambert M, Haro JM, Novick D, et al. Olanzapine vs other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 2005; 111: 232–43

    Article  PubMed  CAS  Google Scholar 

  28. Gasquet I, Haro JM, Novick D, et al. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol 2005; 20: 199–205

    Article  PubMed  Google Scholar 

  29. Novick D, Bousono M, Suarez D, et al. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psychiatry 2005 Jul 13; 29(6): 972–82

    Article  PubMed  CAS  Google Scholar 

  30. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995; 21: 579–91

    Article  PubMed  CAS  Google Scholar 

  31. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychatr Scand 2002; 106: 323–30

    Article  CAS  Google Scholar 

  32. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001; 52: 503–17

    Article  PubMed  CAS  Google Scholar 

  33. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6

    Article  PubMed  CAS  Google Scholar 

  34. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003; 28Suppl. 1: 9–26

    Article  PubMed  CAS  Google Scholar 

  35. Duggan L, Fenton M, Dardennes RM, et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev 2003; (1): CD001359

  36. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; (361): 1581-9

  37. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. JAMA 2003; 290: 2693–702

    CAS  Google Scholar 

  38. Tollefson GD, Birkett MA, Kiesler GM, et al. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Lilly Resistant Schizophrenia Study Group. Biol Psychiatry 2001; 49: 52–63

    CAS  Google Scholar 

  39. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002; 56: 1–10

    Article  PubMed  Google Scholar 

  40. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255–62

    Article  PubMed  Google Scholar 

  41. Beasley CM, Tollefson GD, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111–23

    Article  PubMed  CAS  Google Scholar 

  42. Lieberman JA, Stroup TS, McEvoy JP, et al., for the Clinical antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23

    Article  PubMed  CAS  Google Scholar 

  43. Wahlbeck K, Tuunainen A, Ahokas A, et al. Dropout rates in randomized antipsychotic drug trials. Psychopharmacology (Berl) 2001; 155(3): 230–3

    Article  CAS  Google Scholar 

  44. Haro JM, Novick D, Beiger M, et al., SOHO Advisory Board. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry. In press

  45. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68

    Article  PubMed  CAS  Google Scholar 

  46. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16(1): 23–45

    Article  PubMed  CAS  Google Scholar 

  47. Caroff SN, Mann SC, Campbell EC, et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63Suppl. 4: 12–9

    PubMed  CAS  Google Scholar 

  48. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001; 11Suppl. 4: S397–403

    Article  PubMed  CAS  Google Scholar 

  49. Perkins DO. Predictors of non-compliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121–8

    Article  PubMed  Google Scholar 

  50. Tenback DE, van Harten PN, Slooff CJ, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from European schizophrenia outpatient health outcomes (SOHO) study. J Clin Psychiatry 2005 Sep; 66(9): 1130–3

    Article  PubMed  Google Scholar 

  51. Tenback DE, van Harten PN, Slooff CJ, et al. Evidence that early EPS predicts later tardive dyskinesia: a prospective analysis of 10.000 outpatients with schizophrenia in Europe (SOHO study). Am J Psych. In press

  52. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmcol 2003; 23(3 Suppl. 1): S21–6

    CAS  Google Scholar 

  53. Mclntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001; 62Suppl. 23: 23–9

    Google Scholar 

  54. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96

    PubMed  CAS  Google Scholar 

  55. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158(5): 765–74

    Article  PubMed  CAS  Google Scholar 

  56. Macdonald S, Halliday J, Macewan T, et al. Nithsdale schizophrenia surveys 24: sexual dysfunction: case-control study. Br J Psychiatry 2003; 182: 50–6

    Article  PubMed  CAS  Google Scholar 

  57. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmcol 1997; 17: 407–18

    Article  CAS  Google Scholar 

  58. Bobes J, García-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003; 29: 125–47

    Article  PubMed  CAS  Google Scholar 

  59. Ahl J, Kinon BJ, Liu-Scifert H. Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels. Ann NY Acad Sci 2004; 1032: 289–90

    Article  PubMed  Google Scholar 

  60. Mcgorry PD, Killackey E, Lambert M, et al. Summary Australian and New Zealand clinical practice guidelines for the treatment of schizophrenia. Australas Psychiatry 2003; 11(2): 1–13

    Article  Google Scholar 

  61. Curran MP, Perry CM. Spotlight on amisulpride in schizophrenia. CNS Drugs 2002; 16(3): 207–11

    Article  PubMed  Google Scholar 

  62. Cutler AJ, Goldstein JM, Tumas JA. Related dosing and switching strategies for quetiapine fumarate. Clin Ther 2002; 24(2): 209–22

    Article  PubMed  CAS  Google Scholar 

  63. Williams CL, Johnstone BM, Kesterson JG, et al. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999; 37: AS81–6

    Article  PubMed  CAS  Google Scholar 

  64. Singh MM, Kay SR. Therapeutic antagonism between anti-cholinergics and neuroleptics: possible involvement of cholinergic mechanisms in schizophrenia. Schizophr Bull 1978; 4: 3–6

    Article  Google Scholar 

  65. Sacristan JA, Gomez JC, Montejo AL, et al. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. Clin Ther 2000; 22: 583–99

    Article  PubMed  CAS  Google Scholar 

  66. Parepally H, Chakravorty S, Levine J, et al. The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 437–40

    Article  PubMed  CAS  Google Scholar 

  67. Menzin J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003; 54: 719–23

    Article  PubMed  Google Scholar 

  68. Rocca P, Bellino S, Calvarese P, et al. Depressive and negative symptoms in schizophrenia: different effects on clinical features. Compr Psychiatry 2005; 46(4): 304–10

    Article  PubMed  Google Scholar 

  69. Benson K, Hartz AJ. A comparison of observational studies and randomised, controlled trials. N Engl J Med 2000; 342: 1878–86

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This manuscript has the economic support of the Fondo de Investigaciôn Sanitaria (RIRAG Network – FIS G03/061). Dr Haro has received economic compensation for his participation in the SOHO Advisory Board and has given educational lectures for GlaxoSmithKline and Eli Lilly and Co.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Josep Maria Haro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haro, J.M., Salvador-Carulla, L. The SOHO (Schizophrenia Outpatient Health Outcome) Study. CNS Drugs 20, 293–301 (2006). https://doi.org/10.2165/00023210-200620040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200620040-00003

Navigation